FDMT
Company Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.21M | 37,000 | 20.72M | 3.13M | 18.04M | 13.61M | 6.99M | 14.13M | 5.79M |
| Net Income | (140.11M) | (160.87M) | (100.84M) | (107.49M) | (71.32M) | (56.69M) | (49.31M) | (9.55M) | (11.22M) |
| EPS | -2.42 | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 | -2.00 | -0.76 | -0.76 |
| Free Cash Flow | (109.08M) | (138.37M) | (78.56M) | (98.22M) | (78.24M) | (51.91M) | (39.91M) | (16.67M) | 7.66M |
| FCF / Share | -1.88 | -2.57 | -2.01 | -3.04 | -2.82 | -1.95 | -1.51 | -1.33 | 0.52 |
| Operating CF | (109.08M) | (134.59M) | (75.79M) | (86.69M) | (69.13M) | (50.91M) | (36.71M) | (16.25M) | 8.24M |
| Total Assets | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M | 288.33M | 58.23M | 96.97M | 27.32M |
| Total Debt | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M | 0 | 0 | 0 | 0 |
| Cash & Equiv | 60.24M | 149.34M | 249.11M | 52.35M | 153.00M | 276.73M | 49.65M | 91.76M | 23.85M |
| Book Value | 505.66M | 510.61M | 307.83M | 231.34M | 319.11M | 256.39M | (72.97M) | (27.59M) | (19.59M) |
| Return on Equity | -0.28 | -0.32 | -0.33 | -0.46 | -0.22 | -0.22 | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.05M | 85.09M | 90,000 | 15,000 | 14,000 | 1,000 | 3,000 | 5,000 | 28,000 | (19,000) | 20.20M | 239,000 |
| Net Income | (68.76M) | 19.40M | (56.88M) | (54.66M) | (47.97M) | (49.67M) | (43.84M) | (34.95M) | (32.40M) | (32.28M) | (10.26M) | (29.62M) |
| EPS | -1.01 | 0.34 | -1.01 | -0.98 | -0.86 | -0.90 | -0.79 | -0.63 | -0.66 | -0.83 | -0.24 | -0.77 |
| Free Cash Flow | (68.12M) | 27.92M | (46.41M) | (43.44M) | (48.39M) | (46.81M) | (31.17M) | (30.59M) | (29.80M) | (25.20M) | (1.58M) | (22.87M) |
| FCF / Share | -1.00 | 0.48 | -0.83 | -0.78 | -0.87 | -0.87 | -0.56 | -0.55 | -0.60 | -0.64 | -0.04 | -0.60 |
| Operating CF | (68.12M) | 28.55M | (46.50M) | (43.38M) | (47.76M) | (45.86M) | (29.39M) | (30.24M) | (29.09M) | (24.65M) | (1.17M) | (22.07M) |
| Total Assets | 512.90M | 566.71M | 423.98M | 473.64M | 515.73M | 560.38M | 604.03M | 620.12M | 629.88M | 339.89M | 361.61M | 352.50M |
| Total Debt | 20.54M | 21.41M | 22.26M | 23.08M | 23.85M | 24.61M | 24.83M | 13.66M | 14.17M | 14.67M | 15.16M | 15.63M |
| Cash & Equiv | 72.49M | 60.24M | 48.55M | 77.16M | 133.53M | 149.34M | 187.54M | 189.06M | 275.59M | 249.11M | 275.68M | 236.31M |
| Book Value | 451.84M | 505.66M | 368.98M | 420.89M | 469.72M | 510.61M | 552.95M | 588.34M | 600.56M | 307.83M | 329.93M | 325.14M |
| Return on Equity | -0.15 | 0.04 | -0.15 | -0.13 | -0.10 | -0.10 | -0.08 | -0.06 | -0.05 | -0.10 | -0.03 | -0.09 |
